| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Hepatitis C virus infection: evidence for an association with type 2 diabetes.
|
Diabetes Care
|
2005
|
1.83
|
|
2
|
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer.
|
J Clin Endocrinol Metab
|
2010
|
1.68
|
|
3
|
IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM WHILE IN THERAPY WITH TABLET L-T4, THE LIQUID L-T4 FORMULATION IS MORE EFFECTIVE IN RESTORING EUTHYROIDISM.
|
Endocr Pract
|
2016
|
1.44
|
|
4
|
Endocrine manifestations of hepatitis C virus infection.
|
Nat Clin Pract Endocrinol Metab
|
2009
|
1.30
|
|
5
|
Thyroid disorders in chronic hepatitis C virus infection.
|
Thyroid
|
2006
|
1.21
|
|
6
|
Prevalence of hypothyroidism and Graves disease in sarcoidosis.
|
Chest
|
2006
|
1.15
|
|
7
|
High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism.
|
J Clin Endocrinol Metab
|
2004
|
1.11
|
|
8
|
Dedifferentiated thyroid cancer: a therapeutic challenge.
|
Biomed Pharmacother
|
2008
|
1.08
|
|
9
|
Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
J Clin Endocrinol Metab
|
2005
|
1.07
|
|
10
|
Cytokines and HCV-related disorders.
|
Clin Dev Immunol
|
2012
|
1.02
|
|
11
|
Thyroid cancer in systemic lupus erythematosus: a case-control study.
|
J Clin Endocrinol Metab
|
2009
|
1.00
|
|
12
|
Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
|
Clin Endocrinol (Oxf)
|
2006
|
0.99
|
|
13
|
Prevalence of thyroid dysfunctions in systemic lupus erythematosus.
|
Metabolism
|
2009
|
0.98
|
|
14
|
Increase of CXC chemokine CXCL10 and CC chemokine CCL2 serum levels in normal ageing.
|
Cytokine
|
2006
|
0.96
|
|
15
|
High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia.
|
Clin Rheumatol
|
2009
|
0.94
|
|
16
|
High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection.
|
Am J Gastroenterol
|
2008
|
0.93
|
|
17
|
Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
|
Eur J Endocrinol
|
2006
|
0.90
|
|
18
|
High prevalence of thyroid autoimmunity and hypothyroidism in patients with psoriatic arthritis.
|
J Rheumatol
|
2006
|
0.90
|
|
19
|
Thyroid cancer in HCV-related chronic hepatitis patients: a case-control study.
|
Thyroid
|
2007
|
0.89
|
|
20
|
Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
J Clin Endocrinol Metab
|
2009
|
0.87
|
|
21
|
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia.
|
Autoimmun Rev
|
2008
|
0.87
|
|
22
|
Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis.
|
Metabolism
|
2008
|
0.87
|
|
23
|
Effect of PPAR-gamma activation and inhibition on glucose-stimulated insulin release in INS-1e cells.
|
Diabetes
|
2004
|
0.86
|
|
24
|
RET TKI: potential role in thyroid cancers.
|
Curr Oncol Rep
|
2012
|
0.86
|
|
25
|
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests.
|
Clin Endocrinol (Oxf)
|
2008
|
0.85
|
|
26
|
Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia.
|
Arthritis Rheum
|
2009
|
0.85
|
|
27
|
Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis.
|
Eur J Endocrinol
|
2007
|
0.84
|
|
28
|
Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis.
|
Mod Rheumatol
|
2011
|
0.84
|
|
29
|
CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
|
J Clin Endocrinol Metab
|
2010
|
0.84
|
|
30
|
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
|
J Clin Endocrinol Metab
|
2014
|
0.83
|
|
31
|
Thyroid uptake of 67Ga-citrate is associated with thyroid autoimmunity and hypothyroidism in patients with sarcoidosis.
|
Eur J Nucl Med Mol Imaging
|
2008
|
0.83
|
|
32
|
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
Cytokine
|
2010
|
0.83
|
|
33
|
New targeted molecular therapies for dedifferentiated thyroid cancer.
|
J Oncol
|
2010
|
0.83
|
|
34
|
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
|
J Clin Endocrinol Metab
|
2012
|
0.82
|
|
35
|
High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis.
|
Cytokine
|
2008
|
0.82
|
|
36
|
High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis.
|
Autoimmunity
|
2008
|
0.82
|
|
37
|
New targeted therapies for anaplastic thyroid cancer.
|
Anticancer Agents Med Chem
|
2012
|
0.81
|
|
38
|
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells.
|
Clin Endocrinol (Oxf)
|
2008
|
0.81
|
|
39
|
Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration.
|
Eur J Endocrinol
|
2008
|
0.81
|
|
40
|
N-terminal pro-brain natriuretic peptide and tumor necrosis factor-alpha both are increased in patients with Hepatitis C.
|
J Interferon Cytokine Res
|
2010
|
0.81
|
|
41
|
Age-dependent changes in CXC chemokine ligand 10 serum levels in euthyroid subjects.
|
J Interferon Cytokine Res
|
2005
|
0.80
|
|
42
|
Sorafenib and thyroid cancer.
|
BioDrugs
|
2013
|
0.80
|
|
43
|
Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10.
|
Cytokine
|
2011
|
0.80
|
|
44
|
High circulating levels of N-terminal pro-brain natriuretic peptide and interleukin 6 in patients with mixed cryoglobulinemia.
|
J Med Virol
|
2010
|
0.80
|
|
45
|
Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
|
Metabolism
|
2010
|
0.79
|
|
46
|
Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis.
|
Eur J Endocrinol
|
2005
|
0.79
|
|
47
|
Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer.
|
Cytokine
|
2012
|
0.79
|
|
48
|
Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists.
|
Immunobiology
|
2012
|
0.79
|
|
49
|
Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
|
Thyroid
|
2013
|
0.79
|
|
50
|
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up.
|
J Clin Endocrinol Metab
|
2013
|
0.78
|
|
51
|
Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection.
|
J Rheumatol
|
2009
|
0.78
|
|
52
|
Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children.
|
Surgery
|
2006
|
0.78
|
|
53
|
Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis.
|
J Rheumatol
|
2008
|
0.78
|
|
54
|
Parallel increase of circulating CXCL11 and CXCL10 in mixed cryoglobulinemia, while the proinflammatory cytokine IL-6 is associated with high serum Th2 chemokine CCL2.
|
Clin Rheumatol
|
2013
|
0.78
|
|
55
|
Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
|
J Clin Endocrinol Metab
|
2007
|
0.78
|
|
56
|
Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines.
|
Recent Pat Inflamm Allergy Drug Discov
|
2014
|
0.78
|
|
57
|
Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
|
Endocr Relat Cancer
|
2009
|
0.78
|
|
58
|
High serum levels of CXCL11 in mixed cryoglobulinemia are associated with increased circulating levels of interferon-γ.
|
J Rheumatol
|
2011
|
0.78
|
|
59
|
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis.
|
J Interferon Cytokine Res
|
2009
|
0.77
|
|
60
|
β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
|
J Endocrinol
|
2012
|
0.77
|
|
61
|
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis.
|
J Clin Endocrinol Metab
|
2011
|
0.77
|
|
62
|
Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
|
Exp Cell Res
|
2011
|
0.77
|
|
63
|
Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy.
|
Am J Med Sci
|
2008
|
0.77
|
|
64
|
Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis.
|
J Interferon Cytokine Res
|
2010
|
0.77
|
|
65
|
Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.
|
Mol Cell Endocrinol
|
2011
|
0.77
|
|
66
|
Cytokines and HCV-related autoimmune disorders.
|
Immunol Res
|
2014
|
0.77
|
|
67
|
Increased CXCL9 serum levels in hepatitis C-related mixed cryoglobulinemia, with autoimmune thyroiditis, associated with high levels of CXCL10.
|
J Interferon Cytokine Res
|
2013
|
0.77
|
|
68
|
The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha.
|
Clin Exp Rheumatol
|
2011
|
0.77
|
|
69
|
UV light increases vitamin C uptake by bovine lens epithelial cells.
|
Mol Vis
|
2004
|
0.76
|
|
70
|
Chemokine (CXC motif) ligand 9 serum levels in mixed cryoglobulinaemia are associated with circulating levels of IFN-gamma and TNF-alpha.
|
Clin Exp Rheumatol
|
2012
|
0.76
|
|
71
|
CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes.
|
Curr Drug Targets
|
2016
|
0.76
|
|
72
|
Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity.
|
Recent Pat Endocr Metab Immune Drug Discov
|
2014
|
0.76
|
|
73
|
Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer.
|
Curr Med Chem
|
2016
|
0.76
|
|
74
|
[Extrahepatic manifestations of hepatitis C virus: the thyroid disorders].
|
Recenti Prog Med
|
2005
|
0.75
|
|
75
|
Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
|
J Rheumatol
|
2012
|
0.75
|
|
76
|
Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer.
|
Endocrinology
|
2011
|
0.75
|
|
77
|
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
|
Mini Rev Med Chem
|
2015
|
0.75
|
|
78
|
High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10.
|
J Interferon Cytokine Res
|
2011
|
0.75
|